HEART Score vs TIMI Score for Acute Chest Pain Risk Stratification
For emergency department chest pain evaluation, the HEART score (History, ECG, Age, Risk factors, Troponin) outperforms the TIMI (Thrombolysis In Myocardial Infarction) score and should be your preferred risk stratification tool, as it demonstrates superior discrimination for major adverse cardiac events and identifies more patients suitable for safe early discharge. 1, 2
Key Differences Between the Scores
HEART Score (0-10 points)
- Components: History (0-2), ECG (0-2), Age (0-2), Risk factors (0-2), Troponin (0-2)
- Risk stratification:
- Low risk: 0-3 points (NPV 98.2%, identifies ~40% of patients for discharge) 3
- Intermediate risk: 4-6 points
- High risk: 7-10 points
- Designed specifically for ED chest pain evaluation 1, 2
TIMI Score (0-7 points)
- Components: Age ≥65, ≥3 CAD risk factors, known CAD, aspirin use in past 7 days, severe angina, ST changes, elevated cardiac markers
- Risk stratification:
- Originally developed for patients with established ACS, not undifferentiated chest pain 3
Performance Comparison: Why HEART Wins
Discrimination ability: HEART demonstrates superior receiver operating characteristic curve performance (c-statistic 0.753 vs 0.678 for TIMI), meaning it better separates high-risk from low-risk patients 3. The continuous net reclassification improvement of 0.608 confirms HEART correctly reclassifies significantly more patients 3.
Clinical utility: HEART score ≤3 safely identifies approximately 40% of patients for early discharge with 100% sensitivity for 30-day MACE, compared to TIMI ≤1 identifying only 28% 5, 3. This translates to more appropriate resource utilization without compromising safety.
Guideline endorsement: The 2022 ACC Expert Consensus and 2021 AHA/ACC/SAEM Guidelines specifically recommend the modified HEART score for intermediate-risk patient stratification in the observation zone, while TIMI is listed primarily for comparison purposes 1, 2.
Practical Application Algorithm
Use HEART score when:
- Patient presents with undifferentiated chest pain to the ED
- You need to decide between discharge, observation, or admission
- Serial troponin testing is planned (use at 3-6 hours) 1
- Score ≤3 with negative serial troponins → safe for discharge with outpatient follow-up 1, 2
TIMI may still have limited utility when:
- Patient has confirmed NSTEACS and you're determining invasive strategy timing
- Predicting angiographic severity of known CAD 6, 7
- Score 0 provides excellent NPV (95.2%) but identifies fewer patients than HEART ≤3 6
Critical Pitfalls to Avoid
Don't use TIMI for undifferentiated chest pain: TIMI was validated in patients with established ACS, not for ruling out disease in the ED setting. Using it as your primary tool will miss opportunities for safe early discharge 3.
Beware of troponin assay differences: Both scores perform differently with conventional vs high-sensitivity troponin assays. HEART ≤3 maintains better performance across assay types 4. With high-sensitivity troponin, TIMI score 0 may not achieve 98% sensitivity threshold 4.
Don't ignore the intermediate-risk zone: HEART scores 4-6 require observation with serial troponins at 3-6 hours and repeat risk stratification 1. These patients cannot be safely discharged on initial presentation.
Resource utilization trade-offs: While one study showed HEART increased cardiac diagnostic testing by 2.88-fold compared to TIMI, it simultaneously reduced ED length of stay by 34 minutes without increasing 30-day MACE 8. The increased testing likely reflects more appropriate risk stratification rather than overutilization.
Special Populations
In patients with end-stage renal disease, both scores predict severe coronary atherosclerosis, with optimal cutoffs at HEART 6-7 (AUC 0.754) and TIMI 3-4 (AUC 0.716) 9. However, these cutoffs differ from the general population, so apply standard thresholds cautiously in dialysis patients.
For patients with intermediate troponin elevations (5 ng/L to 99th percentile) where MI is excluded, TIMI score 0 provides the highest NPV (95.2%) for obstructive CAD on subsequent coronary CT angiography, though it only identifies 26% as low-risk 6.